Seagen Inc. (SGEN)
| Previous close | 151.11 |
| Open | 152.21 |
| Bid | 152.05 x 1000 |
| Ask | 152.27 x 1200 |
| Day's range | 150.58 - 153.48 |
| 52-week range | 90.57 - 213.94 |
| Volume | 578,905 |
| Avg. volume | 1,079,927 |
| Market cap | 27.684B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | 45.34 |
| EPS (TTM) | 3.37 |
| Earnings date | 28 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 195.20 |
- Business Wire
Seagen to Present at the Cowen 41st Annual Healthcare Conference
Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seagen’s website at www.seagen.com in the Investors section.
- Business Wire
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV’s accelerated approval to regular approval. The second submission, based on the pivotal trial EV-201’s second cohort, requests an expansion of the current label to include patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and are ineligible for cisplatin.
- PR Newswire
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV's accelerated approval to regular approval. The second submission, based on the pivotal trial EV-201's second cohort, requests an expansion of the current label to include patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and are ineligible for cisplatin.
